Navigating Current and Emerging MS Therapies - What Does the Evidence Say?

CMEO Podcast

Premiere Date: Tuesday, October 22, 2019

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other

Credit Expiration Date: Thursday, December 31, 2020
Note: Credit Is No Longer Available


Aaron Miller, MD, FAAN, FANA Aaron Miller, MD, FAAN, FANA 
Medical Director
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Professor and Vice-Chair for Education
Department of Neurology
Icahn School of Medicine at Mount Sinai
New York, NY

Statement of Need

The recent approval of new disease-modifying therapies (DMTs) for multiple sclerosis (MS) presents many opportunities for clinicians to provide better treatment selection for their patients with MS.

The second episode of this MS CMEOcast series will cultivate the latest evidence on the safety and efficacy of current and emerging therapies for relapsing and progressive MS that was presented at a 2019 well-renowned annual MS meeting, with a goal of translating these findings to treatment decisions that optimize the care of patients with MS.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Assess the latest evidence on efficacy and safety of current and emerging therapies for relapsing and progressive MS.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Assess the latest evidence on efficacy and safety of current and emerging therapies for relapsing and progressive MS.

Financial Support

Supported by educational grants from Biogen and Genentech.

Target Audience

Neurologists, MS specialists, nurse practitioners, physician assistants, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: 0376-0000-19-044-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Miller reports that he receives research support from F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt; MedDay Pharmaceuticals; Novartis Pharmaceuticals Corporation; and Sanofi Genzyme. He is a consultant for Accordant Health Services (Caremark); Adamas Pharmaceuticals, Inc.; Biogen Idec Inc.; Celgene Corporation; Corrona; EMD Serono, Inc.; F. Hoffman-La Roche Ltd.; Genentech, Inc; Mallinckrodt; Mapi-Pharma; and Novartis Pharmaceuticals Corporation. He is on the Speakers Bureau for Biogen Idec, Inc. (unbranded disease awareness programs only); and EMD Serono, Inc. (unbranded journal club).

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kavitha Ramachandran, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

This document was last modified on: